Please replace formula IIIaf on page 28 with the following rewritten formula:

C17




Please replace formula IVo on page 32 with the following rewritten formula:

C18




Please replace formula Vi on page 34 with the following rewritten formula:

C19




Please replace formula Vt on page 36 with the following rewritten formula:

C20




IN THE CLAIMS:

Please amend claims 11, 13, 14, 33, 34, 36, and 38, and enter new claims 41 and 42, as follows:

11. (Amended) A method for providing sedation, mitigating anxiety or providing anaesthesia in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound, wherein the therapeutic compound is of the formula (Ia):

(Ia)



in which $F^2$ is an organic radical which may be joined in a cyclic ring system with $G^2$, and which may contain inorganic counterions, but is not a nitrate group; E is a methylene group and $G^1$ is a methylene group or does not exist; $F^1$ is H; and $G^2$ is $R^N$-$Z^N$-;

wherein $R^N$ is an organic radical possessing a heteroaryl group containing P or S atoms where said P or S are positioned β, γ, or δ to a nitrate group as identified in formula I; and $Z^N$ is $W^N_{mm}$-$X^N_{nn}$-$Y^N_{oo}$;

wherein mm, nn, oo are 0 or 1 and $W^N$, $X^N$, $Y^N$ are NH, $NR^{NN}$, CO, O or $CH_2$;

wherein $R^{NN}$ is a short chain alkyl group ($C_1$ – $C_{12}$).

13. (Twice Amended) A method for providing sedation, mitigating anxiety or providing anaesthesia in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound, wherein the therapeutic compound is of the formula (Ic):

(Ic)



in which E is $(R^1R^2C)_m$ and $G^2$–$G^1$–$CF^1F^2$– is $R^{19}$–$(R^3R^4C)_p$–$(R^{17}R^{18}C)_n$–;

wherein: m, n, p are integers from 0 to 10;

$R^{3,17}$ are each independently hydrogen, a nitrate group, or A; and

$R^{1,4}$ are each independently hydrogen, or A;

where A is selected from a substituted or unsubstituted aliphatic group (comprising a branched or straight-chain aliphatic moiety having from 1 to 24 carbon atoms in the chain, which optionally may contain O, S, $NR^6$ and unsaturations in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted cyclic aliphatic moiety having from 3 to 7 carbon atoms in the aliphatic ring, which optionally may contain O, S, $NR^6$ and unsaturations in the ring, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; an unsubstituted or substituted aliphatic moiety constituting a linkage of from 0 to 5 carbons, between $R^1$ and $R^3$ and/or between $R^{17}$ and $R^4$, which optionally may contain O, S, $NR^6$ and unsaturations in the linkage, and optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups); a substituted or unsubstituted aliphatic group (comprising a branched, cyclic or straight-chain aliphatic moiety having from 1 to 24 carbon atoms in the chain) containing carbonyl linkages (C=O, C=S, C=NOH), which optionally may contain O, S, $NR^6$ and unsaturations in the chain, optionally bearing from 1 to 4 hydroxy, nitrate, amino, aryl, or heterocyclic groups; a substituted or unsubstituted aryl group; a heterocyclic group; an amino group selected from alkylamino, dialkylamino, cyclic amino, diamino and triamino moieties, arylamino, diarylamino, and alkylarylamino; hydroxy; alkoxy; a substituted or unsubstituted aryloxy;

wherein X is F, Br, Cl, $NO_2$, $CH_2$, $CF_2$, O, NH, NMe, CN, NHOH, $N_2H_3$, $N_2H_2R^{13}$, $N_2HR^{13}R^{14}$, $N_3$, S, SCN, $SCN_2H_2(R^{15})_2$, $SCN_2H_3(R^{15})$, $SC(O)N(R^{15})_2$, $SC(O)NHR^{15}$, $SO_3M$, SH, $SR^7$, $SO_2M$, $S(O)R^8$, $S(O)_2R^9$, $S(O)OR^8$, $S(O)_2OR^9$, $PO_2HM$, $PO_3HM$, $PO_3M_2$, $P(O)(OR^{15})(OR^{16})$, $P(O)(OR^{16})(OM)$, $P(O)(R^{15})(OR^8)$, $P(O)(OM)R^{15}$, $CO_2M$, $CO_2H$, $CO_2R^{11}$, C(O), $C(O)R^{12}$, $C(O)(OR^{13})$, $PO_2H$, $PO_2M$, $P(O)(OR^{14})$, $P(O)(R^{13})$, SO, $SO_2$, $C(O)(SR^{13})$, $SR^5$, $SSR^7$ or $SSR^5$;

Y is F, Br, Cl, $CH_3$, $CF_2H$, $CF_3$, OH, $NH_2$, $NHR^6$, $NR^6R^7$, CN, NHOH, $N_2H_3$, $N_2H_2R^{13}$, $N_2HR^{13}R^{14}$, $N_3$, S, SCN, $SCN_2H_2(R^{15})_2$, $SCN_2H_3(R^{15})$, $SC(O)N(R^{15})_2$, $SC(O)NHR^{15}$, $SO_3M$, SH, $SR^7$, $SO_2M$, $S(O)R^8$, $S(O)_2R^9$, $S(O)OR^8$, $S(O)_2OR^9$, $PO_2HM$, $PO_3M_2$, $P(O)(OR^{15})(OR^{16})$, $P(O)(OR^{16})(OM)$, $P(O)(R^{15})(OR^8)$, $P(O)(OM)R^{15}$, $CO_2M$, $CO_2H$, $CO_2R^{11}$, $C(O)R^{12}$, $C(O)(OR^{13})$, $C(O)(SR^{13})$, $SR^5$, $SSR^7$ or $SSR^5$, or does not exist;

$R^2$, $R^5$, $R^{18}$, $R^{19}$ are optionally hydrogen, A or X-Y;

$R^6$, $R^7$, $R^8$, $R^9$, $R^{11}$, $R^{12}$, $R^{13}$, $R^{14}$, $R^{15}$, $R^{16}$ are the same or different alkyl or acyl groups containing 1-24 carbon atoms which may contain 1-4 $ONO_2$ substituents; or $C_1$ - $C_6$ connections to $R^1$ – $R^4$ in cyclic derivatives which may contain 1-4 $ONO_2$ substituents; or are each independently hydrogen, a nitrate group or A;

C22 cont. M is H, $Na^+$, $K^+$, $NH_4^+$, $N^+H_kR^{11}_{(4-k)}$ where k is 0-3; or other pharmaceutically acceptable counterion;

and with the proviso that when m = n = p = 1 and $R^{19}$, $R^2$, $R^{18}$, $R^1$ = H and $R^{17}$, $R^3$ are nitrate groups, $R^4$ is not H.

C23 14. (Amended) The method of claim 11, wherein $F^2$ is a nitrate group; and E, $F^1$, $G^1$, $G^2$ are the same or different organic radicals which may be joined in cyclic ring systems, and which may contain inorganic counterions;

with the proviso that when E and $G^1$ are methylene groups and $F^1$ is H, $G^2$ is not a nitrate group, nor $R^N$-$Z^N$;

wherein $R^N$ is any aryl or heteroaryl group and $Z^N$ is $(CO)_{mm}$-$X^N_{nn}$-$Y^N_{oo}$;

wherein mm, nn, oo are 0 or 1 and $X^N$, $Y^N$ are NH, $NR^{NN}$, O or $CH_2$;

wherein $R^{NN}$ is a short chain alkyl group ($C_1$ – $C_{12}$).

33. (Amended) A method of providing sedation or mitigating anxiety in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound selected from the group consisting of:

C24 IIIa




IIIb




IIIc




IIId



IIIe



IIIf



IIIg



IIIh



IIIi



IIIj




IIIk




C 24 cont.

IIIl




IIIm




IIIn



IIIo




IIIp




IIIq




C24 cont.

IIIr




IIIs



IIIt




IIIu




C24 Cont.

IIIv




IIIw




IIIx




IIIy



IIIz




IIIaa




IIIab




C24 cont.

IIIac




IIIad




IIIae



IIIaf 


IIIag 


IIIah 


C24 Cont.

IIIai 


IIIaj 


IIIak 

IIIal  , and

C24 CONT.

IIIam 

34. (Amended) The method of claim 33, wherein the compound has the formula IIIt:



36. (Amended) A method of providing sedation or mitigating anxiety in a subject in need thereof, comprising administering to a subject an effective amount of a therapeutic compound selected from the group consisting of:

C25

IVa  ,

IVb  ,

IVc 

,

IVd 

,

IVe 

,

C 25
cont.

IVf 

,

IVg 

,

IVh 

,

IVi 

,

IVj 

,

IVk 

,

C25 cont.

IVl 

,

IVm 

,

IVn 

,

IVo 

,

IVp  ,

IVq  ,

IVr  ,

C25 cont.

IVs  , and

IVt 

38. (Amended) A method of mitigating anxiety in a subject in need thereof, comprising administering to ~~a~~ the subject an effective amount of a therapeutic compound selected from the group consisting of:

C26

Va  ,

Vb  ,

Vc  ,

Vd  ,

C26 cont.

Ve  ,

Vf  ,

Vg  ,

Vh  ,

Vi 

,

Vj 

,

Vk 

,

C 26 cont.

Vl 

,

Vm 

,

Vn 

,

Vo 

,

Vp 

,

Vq 

,

C 22 cont.

Vr 

,

Vs 

,

Vt 

,

Vu 

,

Vv 

,

Vw 

,

126 cont.

Vx 

,

Vy 

,

Vz 

,

Vaa 

,

Vab 

,

Vac 

,

C26 cont

Vad 

,

Vae 

,

Vaf 

, and

Vag